137 related articles for article (PubMed ID: 1382848)
1. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Bystryn JC; Henn M; Li J; Shroba S
Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
3. Identification of immunogenic B16 melanoma-associated antigens.
Johnston D; Schachne JP; Bystryn JC
J Biol Response Mod; 1987 Apr; 6(2):108-20. PubMed ID: 3585408
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice.
Johnston D; Bystryn JC
Cancer Immunol Immunother; 2005 Apr; 54(4):345-50. PubMed ID: 15692845
[TBL] [Abstract][Full Text] [Related]
6. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells.
Savage HE; Rossen RD; Hersh EM; Freedman RS; Bowen JM; Plager C
Cancer Res; 1986 Apr; 46(4 Pt 2):2127-33. PubMed ID: 3948184
[TBL] [Abstract][Full Text] [Related]
7. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
Berthier-Vergnes O; Portoukalian J; Lefthériotis E; Doré JF
Cancer Res; 1994 May; 54(9):2433-9. PubMed ID: 8162593
[TBL] [Abstract][Full Text] [Related]
8. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
Hoon DS; Yuzuki D; Hayashida M; Morton DL
J Immunol; 1995 Jan; 154(2):730-7. PubMed ID: 7814879
[TBL] [Abstract][Full Text] [Related]
9. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine].
Takeyama H; Watanabe T; Livingston PO
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1624-33. PubMed ID: 6870307
[TBL] [Abstract][Full Text] [Related]
10. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo.
Applebaum J; Reynolds S; Knispel J; Oratz R; Shapiro R; Bystryn JC
J Natl Cancer Inst; 1998 Jan; 90(2):146-9. PubMed ID: 9450575
[TBL] [Abstract][Full Text] [Related]
11. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotype of human melanoma cells in different metastases.
Bystryn JC; Bernstein P; Liu P; Valentine F
Cancer Res; 1985 Nov; 45(11 Pt 2):5603-7. PubMed ID: 2413993
[TBL] [Abstract][Full Text] [Related]
13. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
[TBL] [Abstract][Full Text] [Related]
14. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.
Riemer AB; Hantusch B; Sponer B; Kraml G; Hafner C; Zielinski CC; Scheiner O; Pehamberger H; Jensen-Jarolim E
Cancer Immunol Immunother; 2005 Jul; 54(7):677-84. PubMed ID: 15565329
[TBL] [Abstract][Full Text] [Related]
15. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
[TBL] [Abstract][Full Text] [Related]
16. Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.
Brown JP; Nishiyama K; Hellström I; Hellström KE
J Immunol; 1981 Aug; 127(2):539-46. PubMed ID: 6166674
[TBL] [Abstract][Full Text] [Related]
17. Immunofluorescent detection of common melanoma membrane antigens by sera of melanoma patients immunized against autologous or allogeneic cultured melanoma cells.
Leong SP; Sutherland CM; Krementz ET
Cancer Res; 1977 Nov; 37(11):4035-42. PubMed ID: 332343
[No Abstract] [Full Text] [Related]
18. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
19. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
20. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]